Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

General Director of Alrosa may become Deputy Finance Minister Alexei Moiseyev

2/23/23 ALRS

NVIDIA's profit for the year decreased by 2.2 times

2/23/23 NVDA

eBay made a loss at the end of 2022

2/23/23 EBAY

Teladoc reported for 2022

2/23/23 TDOC

Abrau-Durso still finds it difficult to work in the PRC market

2/23/23 ABRD

Moscow Exchange decided to delist OR Group shares and bonds

2/23/23 ORUP

Moscow Exchange decided to delist the shares of Mediaholding

2/23/23 ODVA

Moscow Exchange decided to delist GIT shares

2/23/23 GRNT

Moscow Exchange decided to delist MERIDIAN shares

2/23/23 MERF

Moscow Exchange decided to delist the shares of INVEST-DEVELOPMENT

2/23/23 IDVP